Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA interdisciplinary expert consensus / C. Buske, M. Dreyling, A. Alvarez-Larrán, J. Apperley, L. Arcaini, C. Besson, L. Bullinger, P. Corradini, M. Giovanni Della Porta, M. Dimopoulos, S. D'Sa, H.T. Eich, R. Foà, P. Ghia, M.G. da Silva, J. Gribben, R. Hajek, C. Harrison, M. Heuser, B. Kiesewetter, J.J. Kiladjian, N. Kröger, P. Moreau, J.R. Passweg, F. Peyvandi, D. Rea, J.-. Ribera, T. Robak, J.F. San-Miguel, V. Santini, G. Sanz, P. Sonneveld, M. von Lilienfeld-Toal, C. Wendtner, G. Pentheroudakis, F. Passamonti. - In: ESMO OPEN. - ISSN 2059-7029. - 7:2(2022), pp. 100403.1-100403.20. [10.1016/j.esmoop.2022.100403]
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA interdisciplinary expert consensus
P. Corradini;F. Peyvandi;F. PassamontiUltimo
2022
Abstract
Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2059702922000242-main.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
525.53 kB
Formato
Adobe PDF
|
525.53 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
